Skip to content

Total debt at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$445.39M+32.2%
UroGen Pharma logo
UroGen PharmaURGN
$197.09M+56.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$28.6M+10.1%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $16.99M.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s total debt?
Aura Biosciences, Inc. (AURA) reported total debt of $16.99M in Q1 2026.
How has Aura Biosciences, Inc.'s total debt changed year-over-year?
Aura Biosciences, Inc.'s total debt decreased by 7.9% year-over-year, from $18.44M to $16.99M.
What is the long-term trend for Aura Biosciences, Inc.'s total debt?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s total debt has grown at a 105.5% compound annual growth rate (CAGR), from $975K to $17.38M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.